from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY
10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com
, or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street
, Suite 3700, San Francisco, California
94104, or by calling (415) 364-2500.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About NewLink Genetics Corporation
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. NewLink's portfolio includes biologic and small-molecule immunotherapy product candidates intended to treat a wide range of oncology indications.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of NewLink that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "expect," "intend," "may," "will," "could," "should," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among
Page: 1 2 3 Related medicine technology :1
|SOURCE NewLink Genetics Corporation|
Copyright©2012 PR Newswire.
All rights reserved
. NewLink Genetics Corporation Announces Proposed Public Offering of Common Stock2
. Clinical Data from NewLink Genetics HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy3
. Lota S. Zoth joins NewLinks Board of Directors; heads Audit Committee4
. Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)5
. Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics6
. Submit Questions to Nobel Laureates and Other Experts about Genetics and Society7
. The International Serious Adverse Event Consortium and UC San Diego To Collaborate On Research Into The Genetics Of Drug Induced Renal Injury8
. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study9
. Epigenetics R&D Pipeline - Histone Deacetylases (HDACs) Offer the Most Promising Targets and Outnumber Other Classes of Epigenetic Targets10
. Response Genetics, Inc. to Release Second Quarter Financial Results and Host Conference Call on August 14, 201211
. Genelex Receives First Patent on Business Methods for Pharmacogenetics